Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.98 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.71 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.71 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.71 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.71 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.71 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.71 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | TSHR | P16473 | 3/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | ADCY1 | Q08828 | 13/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23659154 | 0.99 | MAPK1 (1.00) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL20034151 | 0.99 | MAPK1 (1.00) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL219972 | 0.99 | MAPK1 (1.00) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL29397687 | 0.99 | MAPK1 (1.00) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| Hydrochloric Acid SCHEMBL1651080 | 0.98 | MAPK1 (0.97) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL2233173 | 0.92 | MAPK1 (0.86) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL7296382 | 0.91 | MAPK1 (0.84) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL7298484 | 0.91 | MAPK1 (0.84) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL16181423 | 0.90 | MAPK1 (0.83) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL7295088 | 0.89 | MAPK1 (0.82) | MAPK1CYP3A4TSHRNR1I2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831933-B1 | METHOD FOR PRODUCING INTESTINAL EPITHELIAL CELLS AND INTESTINAL EPITHELIAL CELLS | FUJIFILM CORP (JP) | 2025-10-29 | — | — | EP | claimed |
| EP-4627061-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| US-12391919-B2 | Culture medium, coating matrix and method for maturing midbrain dopaminergic progenitor cells | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-08-19 | — | — | US | claimed |
| EP-4577641-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| US-20250207092-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-06-26 | — | — | US | claimed |
| CN-119768510-A | Methods and compositions for producing hematopoietic endothelial cells from pluripotent stem cells | 特雷尔赫德生物系统股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| EP-3750985-B1 | METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO INTESTINAL EPITHELIAL CELLS | UNIV NAGOYA CITY PUBLIC UNIV CORP (JP) | 2025-01-22 | — | — | EP | claimed |
| US-12054746-B2 | Method for inducing differentiation of pluripotent stem cells into intestinal epithelial cells | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2024-08-06 | — | — | US | claimed |
| CN-113046300-B | Culture method for preparing keratinocytes based on differentiation of pluripotent stem cells | 上海爱萨尔生物科技有限公司 | 2024-08-06 | — | — | CN | claimed |
| WO-2024151804-A2 | METHODS AND MATERIALS FOR GENERATING STEM CELL-DERIVED ENDOCRINE CELL TYPES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-18 | — | — | WO | claimed |
| US-20230310471-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| US-11725184-B2 | Culture method for organoids | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2023-08-15 | — | — | US | claimed |
| US-20230167458-A1 | FORSKOLIN-INDUCIBLE PROMOTERS AND HYPOXIA-INDUCIBLE PROMOTERS | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2023-06-01 | — | — | US | claimed |
| EP-4136237-A1 | FORSKOLIN-INDUCIBLE PROMOTERS AND HYPOXIA-INDUCIBLE PROMOTERS | Asklepios Biopharmaceutical, Inc. (US) | 2023-02-22 | — | — | EP | claimed |
| EP-4127180-A1 | FORSKOLIN-INDUCIBLE PROMOTERS AND HYPOXIA-INDUCIBLE PROMOTERS | Asklepios Biopharmaceutical, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | Cellapeutics Bio (KR) | 2022-06-16 | — | — | US | claimed |
| WO-2022110494-A1 | METHOD FOR REPROGRAMMING CELL | 北京赛尔湃腾科技咨询合伙企业(有限合伙) | 2022-06-02 | — | — | WO | claimed |
| CN-114480253-A | Culture medium for directional induced differentiation of pluripotent stem cells into hepatocytes, culture method and application | 深圳市三启生物技术有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-111088213-B | Method for inducing stem cells to gradually differentiate to form keratinocytes and keratinocytes | 澳门大学 | 2022-04-08 | — | — | CN | claimed |
| CN-112941015-B | Additive and method for preparing keratinocytes based on differentiation of pluripotent stem cells | 上海爱萨尔生物科技有限公司 | 2022-03-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | GMFG, HGF, BDNF | ADRA1A 4178/4885KCNH2 4100/4885CHRM2 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.